Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

18.7K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
18.7K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.9K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.9K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

13.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.2K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

19.5K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
19.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

4.2K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.2K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

8.7K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety considerations for cereblon-recruiting targeted protein degraders.

Nature reviews. Drug discovery·2026
Same author

Ligandability assessment of interferonopathy-associated proteins using chemoproteomics.

British journal of pharmacology·2025
Same author

Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation.

Molecular cell·2025
Same author

Property-Based Optimization of Cereblon-Based Molecular Glue Degraders.

ACS medicinal chemistry letters·2025
Same author

Introduction to the themed collection on 'Induced-Proximity Pharmacology'.

RSC medicinal chemistry·2025
Same author

Advances in sulfonyl exchange chemical biology: expanding druggable target space.

Chemical science·2025
Same journal

Mechanistic dissection of SMARCA2/4 molecular glues reveals programmable switching between DCAF16 and FBXO22.

Cell chemical biology·2026
Same journal

Beyond the veil of cell death.

Cell chemical biology·2026
Same journal

Assessment of mitochondrial lipid peroxidation in cells and zebrafish using a targeted mass spectrometry probe.

Cell chemical biology·2026
Same journal

Lysine methylation as a bidirectional switch.

Cell chemical biology·2026
Same journal

Quantitative profiling of RNA modifications enriched in non-membrane-bound cellular structures using APEX-RNA-MS.

Cell chemical biology·2026
Same journal

Mechanisms and interventions of epigenetic aging.

Cell chemical biology·2026
See all related articles

Related Experiment Video

Updated: Feb 18, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

Small-Molecule Kinase Downregulators.

Lyn H Jones1

  • 1Jnana Therapeutics, 50 Northern Avenue, Boston 02210, USA.

Cell Chemical Biology
|November 28, 2017
PubMed
Summary
This summary is machine-generated.

New small molecules can now target and degrade harmful kinase proteins. This research compares designed kinase degraders with accidental ones, offering new cancer treatment strategies by disrupting cancer-promoting interactions.

Keywords:
PROTACchemical probedownregulationkinasenon-canonical signalingtarget degradationtranscriptional modulation

More Related Videos

Identification of Kinase-substrate Pairs Using High Throughput Screening
11:13

Identification of Kinase-substrate Pairs Using High Throughput Screening

Published on: August 29, 2015

8.6K
A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening
07:18

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening

Published on: May 12, 2017

6.8K

Related Experiment Videos

Last Updated: Feb 18, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K
Identification of Kinase-substrate Pairs Using High Throughput Screening
11:13

Identification of Kinase-substrate Pairs Using High Throughput Screening

Published on: August 29, 2015

8.6K
A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening
07:18

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening

Published on: May 12, 2017

6.8K

Area of Science:

  • Medicinal Chemistry
  • Oncology
  • Molecular Biology

Background:

  • Kinases play crucial roles in cellular signaling pathways.
  • Dysregulation of kinase activity is implicated in various cancers.
  • Targeting protein-protein interactions is a growing area in cancer therapy.

Purpose of the Study:

  • To explore novel small-molecule kinase ligands.
  • To discuss strategies for downregulating kinase target binding proteins.
  • To evaluate the potential of kinase depletion in cancer treatment.

Main Methods:

  • Comparison of rationally designed heterobifunctional kinase degraders.
  • Analysis of ATP site ligands that induce kinase downregulation.
  • Review of existing literature on kinase function in cancer.

Main Results:

  • Small molecules can be designed to selectively degrade kinase proteins.
  • Serendipitous discovery of kinase downregulation by ATP site ligands offers alternative approaches.
  • Kinase depletion can disrupt pro-oncogenic protein-protein interactions.

Conclusions:

  • Advancements in small-molecule design offer new avenues for kinase targeted therapies.
  • Heterobifunctional degraders and ATP site ligands represent promising strategies for cancer treatment.
  • Targeting kinase-mediated protein-protein interactions via small-molecule depletion holds significant therapeutic potential.